Latest Sjogren’s Research – Antibodies Binds to Nerve Endings. The reason why there are so many nerve-related symptoms in Sjogren’s.
A group of scientists from Adelaide University has found that antibodies found in primary Sjogren’s people’s blood bind to the receptors of tiny nerve endings. These nerve endings are located in glandular structures and other organs and can block the transmission of nerve signals. This signal blocking can result in the various nerve-related symptoms of Sjogren’s Disease.
The research findings will help the understanding and treatment of other autoimmune diseases.
Symptoms of Sjogren’s Disease
Typical Sjogren’s Symptoms are:
- severe dryness of the eyes and mouth
- extensive dental cavities, thrush
- muscle and joint pains – nerve related.
- swollen glands
- Other widespread complaints- fibromyalgia.
Traditional treatments focus on immune suppressants and anti-inflammatories. Most of these drugs include significant side effects that important.
TheraLife Can Help:
TheraLife products are 100% natural.
It addresses the inflammatory aspects of autoimmune diseases; revives and restores normal cell functions intra-cellularly. This multi-pronged approach gradually guides your immune system to be calmer and less likely to flare.
TheraLife Autoimmune Formula work on both Dry Eye and Dry Mouth, Relief Joint Pain, and More!
How Does TheraLife Autoimmune Work?
- Restores normal cell functions to tear secretion and salivary glands
- Regulate immune system to reduce flares.
- Reduce inflammation in joints to reduce pain and restore natural movements.
What is in TheraLife Autoimmune:
TheraLife Eye Autoimmune formula composition :
-1.Immune regulators- to help modulate and regulate the immune system
-2 Strong anti-inflammatories to reduce irritation and inflammation of tear and salivary glands, eyelids, and joints.
-3 To enhance energy without caffeine during the day and helps sleep at night.
to learn more: click here
Follow us at: twitter and Facebook
1.Kaneko Y. [Diagnostic (Classification) Criteria and Treatment Guidelines of Collagen-vascular Diseases: Hos to Use and Cautions on Applying Them for General Physicians. Topics: VII. Sjögren Syndrome]. Nihon Naika Gakkai Zasshi. 2015 Oct;104(10):2149-56.
2.Brito-Zerón P, Retamozo S, Ramos-Casals M. Phenotyping Sjögren’s syndrome: towards a personalised management of the disease. Clin Exp Rheumatol. 2018 May-Jun;36 Suppl 112(3):198-209.
3.Argyropoulou OD, Valentini E, Ferro F, Leone MC, Cafaro G, Bartoloni E, Baldini C. One year in review 2018: Sjögren’s syndrome. Clin Exp Rheumatol. 2018 May-Jun;36 Suppl 112(3):14-26.
4.Baer AN, Akpek EK, Alevizos I., 18-21 April 2018, Washington, DC, USA. 14th International Symposium on Sjögren’s Syndrome. Clin Exp Rheumatol. 2018 May-Jun;36 Suppl 112(3):241-255.
5.Kroese FGM, Haacke EA, Bombardieri M. The role of salivary gland histopathology in primary Sjögren’s syndrome: promises and pitfalls. Clin Exp Rheumatol. 2018 May-Jun;36 Suppl 112(3):222-233.
6.Kiadaliri AA, Mohammad AJ, Englund M. Hospitalizations due to systemic connective tissue diseases: Secular trends and regional disparities in Sweden, 1998-2016. Int J Rheum Dis. 2018 Nov;21(11):1900-1906.
7.Alani H, Henty JR, Thompson NL, Jury E, Ciurtin C. Systematic review and meta-analysis of the epidemiology of polyautoimmunity in Sjögren’s syndrome (secondary Sjögren’s syndrome) focusing on autoimmune rheumatic diseases. Scand J Rheumatol. 2018 Mar;47(2):141-154.
8.Bunya VY, Fernandez KB, Ying GS, Massaro-Giordano M, Macchi I, Sulewski ME, Hammersmith KM, Nagra PK, Rapuano CJ, Orlin SE. Survey of Ophthalmologists Regarding Practice Patterns for Dry Eye and Sjogren Syndrome. Eye Contact Lens. 2018 Nov;44 Suppl 2:S196-S201.
9.Tzioufas AG, Goules AV. Limited efficacy of targeted treatments in Sjögren’s syndrome: why? Clin Exp Rheumatol. 2018 May-Jun;36 Suppl 112(3):27-28.
10.De Vita S, Gandolfo S, Zandonella Callegher S, Zabotti A, Quartuccio L. The evaluation of disease activity in Sjögren’s syndrome based on the degree of MALT involvement: glandular swelling and cryoglobulinaemia compared to ESSDAI in a cohort study. Clin Exp Rheumatol. 2018 May-Jun;36 Suppl 112(3):150-156.
11.Martel A, Coiffier G, Bleuzen A, Goasguen J, de Bandt M, Deligny C, Magnant J, Ferreira N, Diot E, Perdriger A, Maillot F. What is the best salivary gland ultrasonography scoring methods for the diagnosis of primary or secondary Sjögren’s syndromes? Joint Bone Spine. 2019 Mar;86(2):211-217.
12.Baer AN, Walitt B. Update on Sjögren Syndrome and Other Causes of Sicca in Older Adults. Rheum Dis Clin North Am. 2018 Aug;44(3):419-436.
13.Sumida T, Azuma N, Moriyama M, Takahashi H, Asashima H, Honda F, Abe S, Ono Y, Hirota T, Hirata S, Tanaka Y, Shimizu T, Nakamura H, Kawakami A, Sano H, Ogawa Y, Tsubota K, Ryo K, Saito I, Tanaka A, Nakamura S, Takamura E, Tanaka M, Suzuki K, Takeuchi T, Yamakawa N, Mimori T, Ohta A, Nishiyama S, Yoshihara T, Suzuki Y, Kawano M, Tomiita M, Tsuboi H. Clinical practice guideline for Sjögren’s syndrome 2017. Mod Rheumatol. 2018 May;28(3):383-408.
14.Seror R, Mariette X. Guidelines for treatment of primary Sjögren’s syndrome: a first useful stone but still much to do. Rheumatology (Oxford). 2017 Oct 01;56(10):1641-1642.
15.Price EJ, Rauz S, Tappuni AR, Sutcliffe N, Hackett KL, Barone F, Granata G, Ng WF, Fisher BA, Bombardieri M, Astorri E, Empson B, Larkin G, Crampton B, Bowman SJ., British Society for Rheumatology Standards, Guideline and Audit Working Group. The British Society for Rheumatology guideline for the management of adults with primary Sjögren’s Syndrome. Rheumatology (Oxford). 2017 Oct 01;56(10):e24-e48.
16.López-Pintor RM, Fernández Castro M, Hernández G. Oral involvement in patients with primary Sjögren’s syndrome. Multidisciplinary care by dentists and rheumatologists. Reumatol Clin. 2015 Nov-Dec;11(6):387-94.
17.Brito-Zerón P, Theander E, Baldini C, Seror R, Retamozo S, Quartuccio L, Bootsma H, Bowman SJ, Dörner T, Gottenberg JE, Mariette X, Bombardieri S, de Vita S, Mandl T, Ng WF, Kruize AA, Tzioufas A, Vitali C, Buyon J, Izmirly P, Fox R, Ramos-Casals M., Eular Sjögren Syndrome Task Force. Early diagnosis of primary Sjögren’s syndrome: EULAR-SS task force clinical recommendations. Expert Rev Clin Immunol. 2016;12(2):137-56.
18.Milin M, Cornec D, Chastaing M, Griner V, Berrouiguet S, Nowak E, Marhadour T, Saraux A, Devauchelle-Pensec V. Sicca symptoms are associated with similar fatigue, anxiety, depression, and quality-of-life impairments in patients with and without primary Sjögren’s syndrome. Joint Bone Spine. 2016 Dec;83(6):681-685.
19.Flores-Chávez A, Kostov B, Solans R, Fraile G, Maure B, Feijoo-Massó C, Rascón FJ, Pérez-Alvarez R, Zamora-Pasadas M, García-Pérez A, Lopez-Dupla M, Duarte-Millán MÁ, Ripoll M, Fonseca-Aizpuru E, Guisado-Vasco P, Pinilla B, de-la-Red G, Chamorro AJ, Morcillo C, Fanlo P, Soto-Cárdenas MJ, Retamozo S, Ramos-Casals M, Brito-Zerón P., GEAS-SS SEMI Registry. Severe, life-threatening phenotype of primary Sjögren’s syndrome: clinical characterisation and outcomes in 1580 patients (GEAS-SS Registry). Clin Exp Rheumatol. 2018 May-Jun;36 Suppl 112(3):121-129.
20.Al Hamad A, Lodi G, Porter S, Fedele S, Mercadante V. Interventions for dry mouth and hyposalivation in Sjögren’s syndrome: A systematic review and meta-analysis. Oral Dis. 2019 May;25(4):1027-1047.